David Hering, Adagio interim CEO

Ada­gio press­es for­ward with their FDA pitch for Covid an­ti­body — de­spite Omi­cron flaws

Ada­gio, the Till­man Gern­gross biotech whose $750 mil­lion plan to build a pan-coro­n­avirus an­ti­body seem­ing­ly fell apart in the face of Omi­cron, is back again plead­ing its case.

The com­pa­ny re­leased da­ta from its piv­otal tri­als Wednes­day, an­nounc­ing that its an­ti­body ad­in­tre­vimab re­duced the risk of hos­pi­tal­iza­tion or death in par­tic­i­pants with mild to mod­er­ate Covid-19 by 66%, in­clud­ing a 77% re­duc­tion in pa­tients who were treat­ed with­in 3 days of symp­tom on­set.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.